MIAMI, June 10, 2021 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a medical stage biotechnology firm creating mobile therapies for power, aging-related and life-threatening situations, introduced in the present day that its Co-founder and Chairman, Joshua M. Hare, MD, might be a panelist on the National Academy of Medicine’s (NAM) International Workshop on Science & Technology for Healthy Longevity on June 15 & 17, 2021. Dr. Hare will take part within the symposium, “Transformative Advances in Biological Sciences for Healthy Longevity” on Tuesday, June 15 at 5:10 PM EDT. 

The workshop is an integral part of an vital initiative undertaken by the NAM to develop a Global Roadmap for Healthy Longevity, a complete, evidence-based report back to assess the challenges introduced by inhabitants ageing, develop suggestions, and reveal how these challenges will be translated into alternatives for societies globally.

Participants within the Science and Technology workshop will discover and suggest avenues for creating, incentivizing, and funding modern and groundbreaking analysis and growth throughout primary, medical, pharmaceutical, social and behavioral sciences, bioengineering, data know-how, and assistive applied sciences.

“We are honored that our Co-founder, Chairman, and Chief Science Officer, Dr. Hare, has been invited to participate at the prestigious National Academy of Medicine on the subject of healthy aging,” mentioned Geoff Green, Chief Executive Officer of Longeveron. “At Longeveron, our research is focused on developing safe and effective regenerative medicine therapeutics for chronic aging-related diseases and disorders, and we consider ourselves leaders in the field of cell-based therapies for Alzheimer’s disease and Aging Frailty.”

The Company not too long ago accomplished two Phase 2 trials within the U.S. evaluating Lomecel-B for Aging Frailty, a geriatric situation characterised by a multisystem lack of operate and reserve that leaves aged people at larger threat for poor medical outcomes similar to hospitalization, incapacity and demise. Top-line information from these trials are anticipated within the third quarter of this yr. Additionally, Lomecel-B might be examined in Japanese Aging Frailty sufferers in a Phase 2 trial that’s anticipated to provoke within the second half of this yr and is being carried out by Japan’s National Center for Geriatrics & Gerontology and Juntendo University Hospital. The Company’s Alzheimer’s illness program is advancing to a Phase 2 trial this yr after not too long ago efficiently finishing a Phase 1 security trial. The Phase 1 outcomes, beforehand reported by the Company, confirmed that peripheral IV infusion of Lomecel-B in delicate to reasonable Alzheimer’s illness sufferers was protected and well-tolerated, and that low dose Lomecel-B considerably slowed cognitive decline in comparison with placebo as measured by Mini Mental State Exam.

The panel dialogue is open to public audiences and will be accessed through stay webcast here. A hyperlink to register for the presentation can even be obtainable below “Events & Presentations” within the Investors part of the Company’s web site at A replay of the webcast might be accessible on the Longeveron web site for roughly 14 days following the occasion.

About Joshua M. Hare, MD, FACC, FAHA

Dr. Hare co-founded Longeveron in 2014 and serves as Chairman of the Board of Directors, and Chief Science Officer. Dr. Hare is a double board-certified heart specialist (Cardiology and Advanced Heart Failure and Transplantation) and is the founding director of the Interdisciplinary Stem Cell Institute on the University of Miami’s Miller School of Medicine. He has obtained in extra of $25 million in funding from the National Institutes of Health over the previous 15 years to help primary analysis of cell remedy methods. He can also be a recipient of the Paul Beeson Physician Faculty Scholar in Aging Research Award, and is an elected member of the American Association of Physicians, The American Society for Clinical Investigation, and is an elected Fellow of the American Heart Association. Dr. Hare has additionally served in quite a few management roles on the American Heart Association and on the Center for Scientific Review of the National Institutes of Health. Dr. Hare can also be a co-founder of Vestion, Inc., and Heart Genomics, LLC, firms that maintain cardiac associated mental property. He acquired a BA from the University of Pennsylvania, his MD from The Johns Hopkins University School of Medicine, accomplished fellowships at Johns Hopkins and Brigham and Women’s Hospital, and was a Research Fellow at Harvard Medical School.

About the National Academy of Medicine

Founded in 1970 because the Institute of Medicine (IOM), the National Academy of Medicine (NAM) is certainly one of three academies that make up the National Academies of Sciences, Engineering, and Medicine (the National Academies) within the United States. Operating below the 1863 Congressional constitution of the National Academy of Sciences, the National Academies are personal, nonprofit establishments that work exterior of presidency to offer goal recommendation on issues of science, know-how, and well being.

About Longeveron Inc.

Longeveron is a medical stage biotechnology firm creating mobile therapies for particular aging-related and life-threatening situations. The Company’s lead investigational product is the LOMECEL-B™ cell-based remedy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) which might be sourced from bone marrow of younger, wholesome grownup donors. Longeveron believes that by utilizing the identical cells that promote tissue restore, organ upkeep, and immune system operate, it may develop protected and efficient therapies for among the most troublesome problems related to the ageing course of and different medical problems. Longeveron is at the moment sponsoring Phase 1 and 2 medical trials within the following indications: Aging Frailty, Alzheimer’s illness, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left coronary heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and different cell-based product candidates into pivotal Phase 3 trials, with the purpose of attaining regulatory approvals, subsequent commercialization and broad use by the healthcare neighborhood. Additional details about the Company is obtainable at

Forward-Looking Statements

Certain statements on this press launch that aren’t historic info are forward-looking statements that mirror administration’s present expectations, assumptions, and estimates of future efficiency and financial situations, and contain dangers and uncertainties that might trigger precise outcomes to vary materially from these anticipated by the statements made herein. Forward-looking statements are usually identifiable by the usage of forward-looking terminology similar to “believe,” “expects,” “may,” “looks to,” “will,” “should,” “plan,” “intend,” “on condition,” “target,” “see,” “potential,” “estimates,” “preliminary,” or “anticipates” or the destructive thereof or comparable terminology, or by dialogue of technique or objectives or different future occasions, circumstances, or results. Moreover, forward-looking statements on this launch embody, however will not be restricted to, statements concerning the capability of our medical trials to reveal security and efficacy of our product candidates, and different optimistic outcomes; the timing and focus of our ongoing and future preclinical research and medical trials; the dimensions of the market alternative for our product candidates, the useful traits, security, efficacy and therapeutic results of our product candidates; our capability to acquire and preserve regulatory approval of our product candidates, our plans and capability to acquire or shield mental property rights, together with extensions of current patent phrases the place obtainable and our capability to keep away from infringing the mental property rights of others. Further data regarding elements that will influence the Company’s outcomes and forward-looking statements are disclosed within the Company’s filings with the SEC. The forward-looking statements contained on this press launch are made as of the date of this press launch, and the Company disclaims any intention or obligation, apart from imposed by legislation, to replace or revise any forward-looking statements, whether or not on account of new data, future occasions, or in any other case.

Investor Contact:

Brendan Payne
Stern Investor Relations
Office Direct: 212-698-8695 | Office Main: 212-362-1200
[email protected]m |

Source: Longeveron Inc
Source: LGVN


Leave a Reply

Your email address will not be published. Required fields are marked *